Aakaar Medical Technologies IPO Details
Aakaar Medical Technologies IPO Summary
Aakaar Medical Technologies IPO opens for subscription on 20 Jun 2025 and closes on 24 Jun 2025.The IPO will be listed on NSE with the tentative listing date set for 27 Jun 2025.
Aakaar Medical Technologies IPO price band has been fixed at ₹68 – ₹72 per share. The face value is ₹10 per share with a lot size of 1600.
Aakaar Medical Technologies IPO total issue size comprises 37,50,400 shares (aggregating up to ₹27.00 Cr). This includes a fresh issue of 37,50,400 shares (aggregating up to ₹27.00 Cr). Pre-issue shareholding stands at 1,04,22,416, which will increase to 1,41,72,816 post-issue.
Aakaar Medical Technologies IPO carries a ₹0 (0%) GMP, reflecting investor sentiment.
Aakaar Medical Technologies IPO Lot Size :Retail Minimum is 1 lot (1,600 shares) amounting to ₹115,200. Retail Maximum is 1 lot (1,600 shares) amounting to ₹115,200. SHNI Minimum is 2 lots (3,200 shares) amounting to ₹230,400.
The Lead Managers for Aakaar Medical Technologies IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Indorient Financial Services Ltd. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For SME (Small and Medium-sized Enterprise) IPOs, a Market Maker is appointed to ensure liquidity and stability for the stock once it is listed. They do this by continuously quoting bid and ask prices, ensuring there is a market for the shares. The appointed market maker for this IPO is Alacrity Securities. You can analyze their track record by checking the Market Maker Performance Summary report.
For detailed information, Refer to the Aakaar Medical Technologies Limited RHP.
Aakaar Medical Technologies IPO Details
Aakaar Medical Technologies IPO Subscription
Aakaar Medical Technologies IPO Application Wise Breakup
Aakaar Medical Technologies IPO Dates
- 20 Jun 2025Opening dateOpen
- 24 Jun 2025Closing dateClose
- 25 Jun 2025Allotment Date Allotment
- 26 Jun 2025Initiation of RefundsRefund
- 26 Jun 2025Credit of SharesCredit
- 27 Jun 2025Listing dateListing
Aakaar Medical Technologies IPO Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 1600 | ₹115,200 |
| Retail Maximum | 1 | 1600 | ₹115,200 |
| SHNI Minimum | 2 | 3200 | ₹230,400 |
| SHNI Maximum | 0 | 0 | ₹ |
| BHNI Minimum | 0 | 0 | ₹ |
Aakaar Medical Technologies IPO Reservation
Promoter Holding
Documents
Aakaar Medical Technologies IPO Valuations
Aakaar Medical Technologies Financial Information
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
| Assets | 51.85 | 34.01 | 23.23 |
| Revenue | 61.76 | 46.27 | 32.88 |
| Profit After Tax | 6.04 | 2.87 | 2.15 |
| EBITDA | 0.00 | 0.00 | 0.00 |
| Net Worth | 23.20 | 12.53 | 9.66 |
| Reserves and Surplus | 12.78 | 11.84 | 8.96 |
| Total Borrowing | 22.74 | 15.06 | 5.87 |
| Amount in ₹ Crore | |||
About Aakaar Medical Technologies IPO
Incorporated in June 2013, Aakaar Medical Technologies Limited is an aesthetic medical company that offers a diverse selection of specialized cosmetic products and devices.
The company deals in speciality products for Dermatologists, Plastic Surgeons, Aesthetic Physicians, Cosmetologists.
The company's product portfolio encompasses both own brands, which consist of domestically manufactured products and internationally produced devices, and imported brands sourced from countries such as South Korea, Spain, Italy, and Austria.
The company supplies products and devices mainly to dermatologists, plastic surgeons, and aesthetic physicians, who sell them to end consumers and use some consumables in treatments.
The company's product range includes the following:-
- Homecare and professional skin care
- Injectable and contouring, Homecare for skin, Professional Hair Care
- Injectable and contouring, Homecare for skin
- Professional Skincare products
- Hair Growth Serum & Tablets
- Hair Serum, Anti hair loss solution, Tablet
- Medifacial Kit
- Device for urinary incontinence
- Tattoo removal, pigmentation and skin rejuvenation devices
- Laser Hair Reduction devices
- Hair Transplant Device
The company has branches across India with a team of 90 trained sales and service engineers, serving thousands of satisfied customers.
Strength Of Aakaar Medical Technologies IPO
1. Experienced management and leadership teams.
2. Diversified customer base.
3. Diversified product base.
4. Pan India reach through our consignment sales partner.
Risk Of Aakaar Medical Technologies IPO
1. A substantial portion of the revenue is derived from sale of imported third party manufactured brands which exposes it to various risk.
2. The company relies on third party contract manufacturers (domestic and international) & loan licensing partners for manufacturing products & devices which of the sell under its own Brand. the company dependence on third-party manufacturers for the manufacturing of all the products subjects it to certain risks, which, if realized, could adversely affect its business, results of operations, cash flows and financial condition.
3. The company registered office is situated in Maharashtra and the derive a significant portion of the company revenue from state of Maharashtra and Karnataka, making it vulnerable to geographical concentration risk.
4. The company has appointed Parekh Integrated Services Private Limited (PISPL) as a CSA agent for storing, delivering and distributing its products & recovery of dues. Any non-performance or breach of covenants of the CSA agreement executed with PISPL may adversely affect its business operations, profitability and cash flows.
5. Failures to identify and effectively respond to changing consumer preferences, consumer behaviour and spending patterns or changing beauty and personal care trends in a timely manner, may adversely affect the demand for the company products, causing its business, results of operations, financial condition and cash flows.
6. The company may not be able to accurately manage the company inventory, this may adversely affect its business, financial condition and results of operations and reputation.
7. The Company has reported negative cash flow in the past. Any negative cash flows in the future would adversely affect the cash flow requirements, which may adversely affect the company ability to operate the company business and implement its growth plans, thereby affecting its financial condition.
8. As the market for aesthetic treatments grows, the number of clinics and practitioners offering these services is increasing in India which may increase competition among clinics leading to competitive pricing of products. Any change in product pricing will impact revenue and profitability of the business.
9. Its may be subject to unfair competitive or trade practices, like the availability of counterfeit injectables, skincare products, and aesthetic devices, which may reduce the company sales and harm its brands, adversely affecting the company business, financial condition, cash flows and results of operations.
10. Invasive and non-invasive procedures alike carry risks, including infections, scarring, and unintended aesthetic outcomes which may deter the patients from seeking treatments and impact the demand for the products and devices used for these treatments.
Objectives Aakaar Medical Technologies IPO
1. Funding working capital requirements of the Company
2. General corporate purposes
Company Contact Details
Aakaar Medical Technologies Limited
801, Heritage Plaza,
Telli Galli Cross Road
Andheri (East),
Mumbai, Maharashtra, 400069
Phone: +91 84528 44024
Email: companysecretary@aakaarmedical.in
Website: https://aakaarmedical.in/
Registrar Contact Details
Aakaar Medical Technologies FAQs
The Aakaar Medical Technologies IPO is a SME public issue comprising 3750400 equity shares with a face value of ₹10 each, aggregating to a total issue size of ₹27.00 Cr. The issue price has been fixed at ₹72 per equity share, and the minimum application size is 1600 shares.
The IPO opens for subscription on 20 Jun 2025, and closes on 24 Jun 2025.
Bigshare Services Pvt Ltd has been appointed as the registrar to the issue. The equity shares are proposed to be listed on the NSE
As of now, the current GMP stands at ₹0 (0%).
Quick Links
Comments
